Emory university- fluvid, a dry powder, inhaled, mrna-based treatment for influenza and covid
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50124C00039
- Awardee
-
Emory University UEI VXVCN6LFAZ84
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $490,376
Award facts
- Opportunity
-
- BAA20SOL0003 Solicitation number
- Contract value 100% obligated
- $490,376.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Atlanta, GA 30329, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$259,622 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $749,998 |
About this award
Emory University was awarded a $490,376 definitive, firm-fixed-price contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) on August 22, 2024, to develop FLUVID, an innovative dry powder, inhaled, mRNA-based treatment for influenza and COVID-19. The contract, with an ultimate completion date of August 5, 2025, will be performed in Atlanta, Georgia, and carries no set-aside designation. ASPR, a civilian agency within the Department of Health and Human Services, supports this work as part of its mission to strengthen preparedness and response capabilities for public health emergencies and medical countermeasures.
This contract reflects Emory University's established expertise in advanced pharmaceutical research and development, particularly in addressing urgent public health threats through cutting-edge medical innovations. The mRNA-based therapeutic approach represents a significant advancement in pandemic preparedness and treatment options, leveraging the institution's strong research capabilities and alignment with federal health security priorities.
Quick answers
Who was awarded contract 75A50124C00039?
75A50124C00039 was awarded to Emory University by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on August 22, 2024.
How much is contract 75A50124C00039 worth?
The government has obligated $490,376 on 75A50124C00039.
Was contract 75A50124C00039 competed?
The extent of competition for 75A50124C00039 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award